Schizophrenia. Schizophrenia
Conditions
Interventions
Intervention 1: Intervention group: The drug used is l-carnitine 1000 mg, which is given to the intervention group daily for eight weeks, which is completely similar to the placebo drug in terms of we
Sponsors
Sanandaj University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 50 Years
Inclusion criteria
Inclusion criteria: Schizophrenia according to DSM-5 Absence of any other disease that negatively affects the patient's cognitive processes (dementia, hypothyroidism, intellectual disability, ID... based on clinical interview) receiving a fixed dose of drugs such as anticholinergics (bipyridine...) and benzodiazepines during the last 1 month Receiving regular standard treatment and having a stable and controlled clinical condition during the last 1 month
Exclusion criteria
Exclusion criteria: Coexistence of another psychiatric disorder according to DSM-5 Received ECT in the past 2 months Coexistence of substance abuse disorder and methadone according to DSM-5 Taking any medication that is prescribed due to cognitive problems or significantly affects the patient's cognitive processes
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Increasing the cognitive abilities of patients with schizophrenia following the administration of L-carnitine. Timepoint: The beginning, middle and end of the study. Method of measurement: Wechsler Memory Scale Questionnaire (WMS) and Brief Mental State Examination (MMSE). | — |
Secondary
| Measure | Time frame |
|---|---|
| Changes in CRP serum levels. Timepoint: The beginning and end of the study. Method of measurement: Serum sample collection and quantitative measurement of CRP. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactNarges Shamsalizadeh
Sanandaj University of Medical Sciences
Outcome results
None listed